GlassScriptPhysician profile
Mark J Glanzer
NPI 1336121003
$2,086.60
in general payments reported to CMS, 2019-2025
17 companies · $277 in 2025
The $277 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $263 · 2020: $29.60 · 2021: $76.70 · 2022: $485 · 2023: $363 · 2024: $593 · 2025: $277.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,233.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,232.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $279.89 | 2019-2025 | Argos, Rocklatan, Clareon |
| Bausch & Lomb Americas INC. | $272.95 | 2022-2025 | Vyzulta, Xiidra, Zylet |
| Notal Vision, INC. | $267.56 | 2022 | |
| Biotissue Holdings INC. | $233.06 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $203.73 | 2019-2025 | Cequa |
| Oyster Point Pharma, INC. | $154.81 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Abbvie INC. | $130.14 | 2022-2024 | |
| Glaukos Corporation | $121.51 | 2019-2025 | Idosetr |
| Novartis Pharmaceuticals Corporation | $115.38 | 2019-2023 | |
| Tearlab Corp | $78.98 | 2023-2024 | Scoutpro Osmolarity System, Tearlab Osmolarity System |
| Harrow Eye, LLC | $59.16 | 2024-2025 | Vevye |
| Allergan, INC. | $57.38 | 2019-2022 | |
| Shire North American Group INC | $34.10 | 2019 | |
| Amgen INC. | $25.18 | 2024 | Tepezza |
| Johnson & Johnson Surgical Vision, INC. | $19.55 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $17.40 | 2021 | |
| Dompe US, INC. | $15.82 | 2025 | Oxervate |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Glanzer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.